
January/February 2006
Adam Goldstein, David Schieche, Amy Manocchi, Ravi Samavedam, Lindsay Wilkinson
Amgen, Inc.
Douglas G. Perry, Ph.D.
Jean M. Surian, Ph.D.
Pharmaceutical and Analytical R&D
AstraZeneca Pharmaceuticals
Arwa El Hagrasy, Shih-Ying Chang, Divyakant Desai, and San Kiang
Bristol-Myers Squibb Company
Joan Ruan, Peter Tattersall, Ruben Lozano, Pankaj Shah
Analytical Research & Development
Bristol-Myers Squibb
Niklas Sandler, Ph.D.
University of Otago
Deborah E. Mentel
Pfizer Global Research & Development
David Hussong, Ph.D., and Robert Mello, Ph.D.
New Drug Microbiology Staff, Office of Pharmaceutical Science, Center for Drug Evaluation of Research
U.S. Food and Drug Administrations
Carey Newton, CIH, MSPH
Eli Lilly & Company
Anthony E. Dowrey, Gloria M. Story, and Curtis Marcott, Ph.D.
The Procter & Gamble Company
Danielle Giron
Novartis Pharma
Narlin Beaty, Ph.D.
Sublimation Science
Robert A. Carlton
Investigator, Physical Properties, GlaxoSmithKline
Yihong Qiu
Global Formulation Sciences, Global Pharmaceutical Research and Development
Abbott Laboratories
1Nicholas Bodor and 2Peter Buchwald
1Center for Drug Discovery, University of Florida
2IVAX Research, Inc.